Study on the material basis and molecular mechanism of clinical effective traditional Chinese Medicine

September 2010 -- September 2015: student / doctoral degree of Dalian Institute of Chemical Physics, Chinese Academy of Sciences

September 2006 to July 2010 Shandong Normal University Student / Bachelor degree

June 2019 ~ now, associate researcher, Dalian Institute of Chemical Physics, Chinese Academy of Sciences

November 2015 to June 2019, assistant researcher, Dalian Institute of Chemical Physics, Chinese Academy of Sciences

   

（1） Label-free cell phenotypic study of opioid receptors and discovery of novel mu opioid ligands from natural products, Journal of Ethnopharmacology, 2021
（2） Identification and target-pathway deconvolution of FFA4 agonists with anti-diabetic activity from Arnebia euchroma (Royle) Johnst, Pharmacological Research, 2021

（3） Scocycamides, a Pair of Macrocyclic Dicaffeoylspermidines with Butyrylcholinesterase Inhibition and Antioxidation Activity from the Roots of Scopolia tangutica, Organic Letters, 2020
（4）Isolation and bioactive evaluation of flavonoid glycosides from Lobelia chinensis Lour using two-dimensional liquid chromatography combined with label-free cell phenotypic assays, Journal of Chromatography A, 2019
（5）Saikosaponin D from Radix Bupleuri suppresses triple-negative breast cancer cell growth by targeting beta-catenin signaling, Biomedicine & Pharmacotherapy, 2018
（6）Discovery of 2H-Chromen-2-one Derivatives as G Protein-Coupled Receptor-35 Agonists, Journal of Medicinal Chemistry, 2017

(1) A histamine H1 receptor antagonist and its screening method and application, invention, 2019, 5th author, patent No.: 201510612612.0

(2) Application of a coumarin derivative in the preparation of drugs for the treatment of inflammatory enteritis, invention, 2021, the second author, patent No.: 202010914441.8

(3) Application and pharmaceutical composition of atractylone or atractylodin as ffa1 agonist, invention, 2021, the third author, patent No.: 202010919683.6

(4) A cell screening model for label free membrane receptor gpr84 and its application, invention, 2021, the third author, patent No.: 202010894186.5

(1) Label free cell pharmaceutical identification of active compounds in traditional Chinese medicine, Springer, 2015-04, the second author

Study on the construction of evaluation system of pharmacodynamic activity of traditional Chinese Medicine

Study on lead active compounds of traditional Chinese Medicine

Mechanism analysis of clinical effective prescriptions

 4th International Conference on Traditional Medicine, Phytochemistry and Medicinal Plants

(1) Liaoning Province "the project of promoting Liaoning talents" high level innovation and entrepreneurship team, provincial level, 2019

(1) Based on β 2 and M3 target pathway of curcuma zedoary anti COPD active ingredients and integrated mechanism, chair, national level, January 2019 to December 2021 

(2) Discovery and efficacy study of ATP citrate lyase inhibitor based on materia medica database, presided over, municipal level, August 2020-august 2022 

(3) Research and application of precision control technology of genuine medicinal materials in Liaoning, participation, Research Institute (school), January 2020 to December 2022 

(4) Research on new anti COPD muscarinic receptor drugs from traditional Chinese medicine, participated in, municipal level, August 2019 to July 2021

(5) Study of anti-TNBC effective components from traditional Chinese medicines based on 3D cellular spheroid models and dynamic mass redistribution technology, January 2022 to December 2025